FDA Compliant Handling of Out-of-Trend Results in Pharmaceutical Quality Control
Learn how to investigate and document out-of-trend results in pharmaceutical QC using FDA's OOS guidance, historical data, control charts, root cause analysis and CAPA.
Speaker
Kelly Thomas
cGMP quality and validation consultant · 20+ years in cGMP industry
Overview
FDA's guidance on investigating out-of-specification (OOS) test results calls for failure investigations, and notes that much of it can also help when examining out-of-trend (OOT) results. This 90-minute webinar explains FDA requirements and guidelines for handling out-of-trend results in the pharmaceutical laboratory.
You'll review the relevant FDA regulations and the final Guidance for Industry on investigating OOS results, how OOS and OOT results differ, and how to write SOPs for OOT situations and laboratory failures. The session covers what to investigate and how, retesting, and evaluating results with historical data, QC samples and product control charts.
It also explains how to find the root cause, develop CAPA plans, prevent OOS results before they happen, and document OOS, OOT, investigations, root causes and CAPA in an FDA-compliant way.
Why attend: Most companies have procedures for OOS results but not for OOT situations, and many are unsure how to interpret and apply FDA's guidance to them. Managing OOT results well also helps you avoid time-consuming OOS investigations later. This session suits lab supervisors and managers, QA managers and staff, pharmaceutical R&D and documentation personnel, consultants, contract laboratories and CROs.
What’s covered
- FDA regulations and guidelines
- FDA's final Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production
- The difference between OOS and OOT results
- Developing SOPs for OOT situations and laboratory failures
- Investigating OOT results: what and how
- Retesting OOT results
- Using historical data for OOT evaluation
- Using QC samples and product control charts
- Developing corrective and preventive action plans
- Finding the root cause of OOT results
- Strategies to prevent OOS situations before they occur
- FDA-compliant documentation of OOS, OOT, failure investigations, root causes and CAPA
Who should attend
What you get
About the speaker
Ms. Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation.
Utilizing strategic thinking, risk based approaches, and Lean principles, she has demonstrated success in steering and managing complex projects within the pharmaceutical and medical device industries.
More in FDA Compliance
See all 46 FDA webinars →
Ms. Michael Redmond · 60 min
Excel Spreadsheets; Develop and Validate for 21 CFR Part 11 Compliance
David Nettleton · 75 min
Medical Device Cybersecurity Following FDA’s 2026 Premarket Guidance
Edwin Waldbusser · 75 min
Performance of Root Cause Analysis, CAPA, and Effectiveness Checks
Meredith Crabtree · 90 min